An expert review on the use of tenofovir alafenamide for the treatment of chronic hepatitis B virus infection in Asia
- PDF / 298,728 Bytes
- 13 Pages / 595.276 x 790.866 pts Page_size
- 36 Downloads / 179 Views
REVIEW
An expert review on the use of tenofovir alafenamide for the treatment of chronic hepatitis B virus infection in Asia Michael R. Charlton1 • Altaf Alam2 • Akash Shukla3 • Bekhbold Dashtseren4 • Cosmas Rinaldi Adithya Lesmana5 • Davadoorj Duger6 • Diana Alcantara Payawal7 • Do Duy Cuong8 • Ganbolor Jargalsaikhan9,10,11 • Ian Homer Yee Cua12 • Jose Decena Sollano13 • Karam Romeo Singh14 • Kaushal Madan15 • Khin Maung Win16 • Khin Pyone Kyi17 • Kyaw Soe Tun18 • Mohd. Salih19 • Mukul Rastogi20,21 • Neeraj Saraf22 • Pham Thi Thu Thuy23 • Pham Tran Dieu Hien24 Rino Alvani Gani25 • Rosmawati Mohamed26 • Tawesak Tanwandee27 • Teerha Piratvisuth28 • Wattana Sukeepaisarnjaroen29 • Win Naing30 • Zahid Yasin Hashmi31
•
Received: 18 February 2020 / Accepted: 25 May 2020 The Author(s) 2020
Abstract Asia has intermediate-to-high prevalence and high morbidity of hepatitis B virus (HBV) infection. The use of guideline-recommended nucleos(t)ide analogs with high barrier to resistance, such as entecavir (ETV), tenofovir disoproxil fumarate (TDF), and tenofovir alafenamide (TAF), is one of the key interventions for curbing HBV
infection and associated morbidity in Asia. However, there are some challenges to the use of ETV and TDF; while ETV is associated with high resistance in lamivudine (LAM)-exposed (especially LAM-refractory) patients; bone and renal safety issues are a major concern with TDF. Hence, a panel of twenty-eight expert hepatologists from 12
Research Committee and Social Committee, Institute of Digestive and Liver Diseases, St. Luke’s Medical Center, Taguig, Philippines
13
Department of Medicine, University of Santo Tomas Hospital, Manila, Philippines
14
Liver Clinic, Regional Institute of Sciences, Imphal, India Gastroenterology & Hepatology, Max Smart Super Speciality Hospital, Saket, New Delhi, India
& Michael R. Charlton [email protected] 1
Transplant Institute, Center for Liver Diseases, University of Chicago Biological Sciences, 5841 South Maryland Avenue, Chicago, Illinois, USA
2
GI Hepatology, Lahore, Pakistan
15
3
Department of Gastroenterology, LTM Medical College and Sion Hospital, Maharashtra, Mumbai, India
16
University of Medicine (1) YGN, Yangon, Myanmar
4
Liver Center Hospital, Ulaanbaatar, Mongolia
17
5
Department of Internal Medicine, Hepatobiliary Division, Dr. Cipto Mangunkusumo Hospital, Universitas Indonesia, Jakarta, Indonesia
Myanmar Liver Foundation, Liver Foundation, Yangon, Myanmar
18
Myanmar GI and Liver Society, Yangon, Myanmar
19
Department of Hepatology, Quaid e Azam International Hospital, Islamabad, Pakistan
20
Department of Hepatology and Gastroenterology, Fortis Hospital, Noida, India
21
Department of Transplant Hepatology, Fortis Hospital, Noida, India
22
Clinical/Transplant Hepatology Institute of Digestive and Hepatobiliary Sciences Medanta, The Medicity, Gurgaon, New Delhi, India
23
Department of Medic Medical Center, Ho Chi Minh City, Vietnam
6
Mongolian National University of Medical Sciences, Ulaanbaatar, Mongolia
Data Loading...
